MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$9,243K
EPS
-$0.08
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
Research and development
4,552 3,329*
General and administrative
4,729 3,853*
Total operating expenses
9,281 7,181
Loss from operations
-9,281 -7,181*
Change in fair value of warrant derivative
0 -38*
Fair value loss from standby equity purchase agreement (sepa arrangement)
--97*
Foreign exchange loss
-6 -26*
Interest income
44 97*
Total other income, net
38 11*
Loss before income taxes
--7,170*
Income tax expense
-20*
Net loss
-9,243 -7,190*
Translation adjustments
0 -34*
Comprehensive loss
-9,243 -7,224
Basic EPS
-0.08 -0.075
Diluted EPS
-0.08 -0.075
Basic Average Shares
112,292,579 95,857,147
Diluted Average Shares
112,292,579 95,857,147
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$9,243K Interest income$44K Net loss-$9,243K Total other income,net$38K Foreign exchange loss-$6K Loss from operations-$9,281K Total operatingexpenses$9,281K General andadministrative$4,729K Research and development$4,552K

ONCOLYTICS BIOTECH INC (ONCY)

ONCOLYTICS BIOTECH INC (ONCY)